晚期原发性肝癌免疫治疗期间肠道菌群纵向动态识别临床获益微生物特征
本研究对315例接受免疫检查点抑制剂(ICI)治疗的晚期原发性肝癌患者进行前瞻性纵向鸟枪法宏基因组研究,分析777份系列粪便宏基因组。应答者基线α多样性更高且群落结构不同,治疗期间两组均出现显著生态重塑。基于约6个月治疗窗口发现的16种菌群面板构建的基线模型,在9个公共ICI队列(n=1204)中泛化良好,并可分层总生存和无进展生存。
要点
- 应答者基线α多样性更高且群落结构独特
- 治疗约6个月为特征发现最佳窗口,识别16种菌面板
- 该面板构建的基线模型在9个公共队列中可泛化并分层生存
核心结论
- ICI治疗期间肠道菌群发生结构化生态重塑,治疗中纵向窗口可提高 pretreatment 特征的可移植性并支持微生物组指导的分层。
研究设计与样本
- 前瞻性纵向鸟枪法宏基因组研究,纳入315例接受ICI为基础治疗的晚期原发性肝癌患者,采集777份基线和约每3个月一次的系列粪便宏基因组。
- 应答者(持久临床获益≥6个月)随访超过18个月,治疗中窗口用于特征发现,基线训练模型在9个公共ICI队列(n=1204)中评估。
主要发现
- 应答者基线α多样性更高且群落结构不同。
- 纵向分析显示两组治疗期间均出现显著生态重塑,表现为网络连接减少、模块性增加和判别物种的时间点特异性。
- 以约6个月治疗对比(T2)为发现窗口,识别出16种菌面板,基于该面板的基线模型优于仅基线特征发现模型,并在9个公共ICI研究中泛化。
- 肠道微生物组衍生的免疫治疗结局评分在发现队列中分层总生存和无进展生存(HR分别为0.49和0.44),并在多个外部数据集(包括稳定疾病亚组)中验证。
关键数值与推荐
- 应答定义为持久临床获益≥6个月。
- 发现窗口为治疗约6个月(T2),识别16种菌面板。
- 结局评分在发现队列中总生存HR 0.49,无进展生存HR 0.44。
临床怎么用
- 治疗中纵向微生物组采样可提升基线生物标志物特征的泛化能力,支持在免疫肿瘤学中开展微生物组指导的风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The gut microbiome has been linked to immune checkpoint inhibitor (ICI) outcomes, but the temporal dynamics of microbial communities during treatment remain poorly characterised. OBJECTIVE: To characterise gut microbiome trajectories during ICI therapy and evaluate whether on-treatment microbial states improve the identification and generalisability of pretreatment biomarker signatures. DESIGN: We performed a large prospective longitudinal shotgun metagenomic study of 315 patients with advanced primary liver cancer receiving ICI-based therapy, profiling 777 serial stool metagenomes collected at baseline and at approximately 3-month intervals on treatment. Responders (durable clinical benefit ≥6 months) contributed extended follow-up beyond 18 months. On-treatment windows were used for feature discovery; baseline-trained models were evaluated across all nine public ICI cohorts (n=1204). RESULTS: Responders showed higher baseline alpha diversity and distinct community structure. Longitudinal profiling revealed marked ecological remodelling during therapy in both response groups, characterised by reduced network connectivity, increased modularity and strong time point specificity of discriminatory species. Using the on-treatment contrast at ~6 months (T2) as a discovery window, we identified a 16-species panel. A baseline model built from this panel outperformed models based on baseline-only feature discovery and generalised across nine public ICI studies. The resulting gut microbiome-derived immunotherapy outcome score stratified overall and progression-free survival in the discovery cohort (HRs 0.49 and 0.44) and across multiple external datasets, including stable-disease subsets. CONCLUSION: The gut microbiome undergoes structured ecological remodelling during ICI therapy; on-treatment longitudinal windows improve pretreatment signature portability and support microbiome-guided stratification in immuno-oncology.
引用
- Qian Z, Han J, Lyu B, et al. Longitudinal gut microbiome dynamics during immunotherapy identify microbial features of clinical benefit in advanced primary liver cancer. Gut. 2026. PMID: 42749361. doi:10.1136/gutjnl-2026-339115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。